Navigation Links
Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer

esothelin (p=.01). The new findings were presented over the weekend by Daniel Laheru, M.D., assistant professor of medical oncology at Johns Hopkins Kimmel Cancer Center, and colleagues, at the 2007 American Society of Clinical Oncology (ASCO) annual meeting being held in Chicago, IL.

"We continue to be encouraged by the survival data analysis, as well as the immunologic data reported today in this Phase 2 study of GVAX immunotherapy for pancreatic cancer in patients with operable disease," said Kristen Hege, M.D., vice president of Clinical Research at Cell Genesys. "We look forward to the results of ongoing studies conducted by Johns Hopkins which include a study of booster administrations to patients in the completed Phase 2 trial as well as a second 60-patient Phase 2 trial of GVAX immunotherapy with booster administrations following pancreatic cancer surgery and adjuvant radiation and chemotherapy. In addition, we are also looking forward to the results of a third ongoing Phase 2 trial in patients with metastatic pancreatic cancer also being conducted by Johns Hopkins, which is evaluating GVAX immunotherapy in combination with Erbitux(R), an antibody to the EGF receptor."

The Phase 2 study reported today was designed to evaluate the safety and efficacy of GVAX immunotherapy for pancreatic cancer which is being developed as a non patient-specific "off-the-shelf" pharmaceutical product. All patients underwent extensive surgical resection of their tumors. The immunotherapy was administered as an intradermal (under the skin) injection before and after standard post-operative adjuvant radiation therapy and 5- flourouracil chemotherapy. Patients received up to five doses -- the first prior to adjuvant chemoradiotherapy, the next three following adjuvant therapy at approximately one-month intervals and the fifth as a booster injection six months later. Patients were monitored for evidence of relapse an
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response
2. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:3/27/2015)... , March 27, 2015  Valeant Pharmaceuticals International, ... the closing of its previously announced registered offering of ... (the "Offering"). Pursuant to the Offering, the Company ... per share, for aggregate gross proceeds of approximately $1.45 ... the U.S. Securities and Exchange Commission a final prospectus ...
(Date:3/27/2015)... March 27, 2015 As of February, ... incontinence devices for women. "Shipping thousands ... gratifying part is the hundreds of letters, emails ... lives have been positively impacted by our technology," ... InControl recently released Apex, an over-the-counter ...
(Date:3/27/2015)... , March 27, 2015   Hospira, ... leader in biosimilars and the world,s leading provider ... studies that support an evaluation of biosimilarity of ... Food and Drug Administration (FDA) conditionally approved name ... EPOGEN™ (epoetin alfa). These study data were presented ...
Breaking Medicine Technology:Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3
... in Improving Symptoms and Urine Flow, With,Long Lasting ... 23, 2007 /PRNewswire-FirstCall/ -- Spectrum,Pharmaceuticals, Inc., today announced ... Company's drug candidate for the treatment,of benign prostatic ... held at the Anaheim Convention Center in,Anaheim, California ...
... WIRE)--May 23, 2007 - Northfield,Laboratories, Inc. (NASDAQ: ... III trauma trial with PolyHeme(R), its human,hemoglobin-based ... designed to seek an indication for use ... loss when transfusion is,required and red blood ...
Cached Medicine Technology:Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 2Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 3Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 4Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 5Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 2Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 3Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 4Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 5Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 6Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 7Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 8
(Date:3/29/2015)... 2015 The Contract Research Organizations ... research, manage data results and help develop and ... regulation standards. Contract research organizations (CROs) mainly serve ... sectors. Industry operators provide clients with a full ... research for Food and Drug Administration (FDA) approval. ...
(Date:3/29/2015)... Franklin, TN (PRWEB) March 29, 2015 ... for several PT Online Continuing Education Courses . ... - 10.0 hours of CME - TPTA, approval # ... Master the evaluation of the shoulder complex - 10.5 ... Course Approved #56400TX , Examination and Treatment of the ...
(Date:3/28/2015)... "Necrorun" was featured on NewsWatch as part of ... latest and coolest applications on the market for iOS, ... and technology expert, conducted the app review and shared ... game with knights, nature, and peasants. , The ... to Eurogamer. The popularity of these games grew over ...
(Date:3/28/2015)... NY (PRWEB) March 28, 2015 Emergency ... offers urgent care in Manhattan, recently commemorated its three-year ... facility in Manhattan. In addition to 24-hour urgent care, ... facilities. , At this time, Emergency Medical Care’s ... abdominal pain, asthma, chest pain, eye injuries, ear infections, ...
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 One ... re-injury, according to research presented today at the American ... Day. The study examined the long term success of ... , “We examined survey data from 242 patients who ... author Justin P. Roe, MBBS, FRACS, from North Sydney ...
Breaking Medicine News(10 mins):Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 4Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2
... Gardasil, study finds, , TUESDAY, Aug. 18 (HealthDay News) ... a cause of cervical cancer, appears safe, with relatively ... government study. , The study, which included data ... found that the rate of serious adverse events for ...
... ... specializing in healthy and natural dog treats announced today the official launch of its ... for a qualified veterinarian. All licensed U.S. veterinarians may list their practice in ... ...
... BURLINGTON, Mass., Aug. 18 Palomar Medical Technologies, ... developer of light-based systems for cosmetic treatments, announced today that ... confirmed the validity of all claims in the re-examination of ... Removal Using Optical Pulses." , , Rejecting ...
... , OAKLAND, Calif., Aug. 18 The ... Older Adults Maintain Independence: Advancing Technology Adoption," a briefing paper ... chronic health care and increasing the independence of older adults, ... "Spending on hospitalizations and chronic care management now exceeds ...
... , Price of Diabetes Prevention ... , , BETHESDA, Md., Aug. 18 ... with diabetes has been misconstrued during recent health care reform ... nation,s leading professional organization of doctors of podiatric medicine (DPMs), ...
... , , , ... (JCMC), the 488 bed, Magnet-designated flagship hospital of Mountain States Health Alliance (MSHA), ... Smart S q uare , the enterprise scheduling software ... live with Smart Square, JCMC has realized a savings of nearly $550,000 associated ...
Cached Medicine News:Health News:Cervical Cancer Vaccine Seems Safe 2Health News:Cervical Cancer Vaccine Seems Safe 3Health News:FidoDogTreats.com Launches Veterinarian Directory 2Health News:Palomar Successful in U.S. Patent Office Re-Examination of Second Hair Removal Patent 2Health News:Palomar Successful in U.S. Patent Office Re-Examination of Second Hair Removal Patent 3Health News:Palomar Successful in U.S. Patent Office Re-Examination of Second Hair Removal Patent 4Health News:Palomar Successful in U.S. Patent Office Re-Examination of Second Hair Removal Patent 5Health News:Center for Technology and Aging Brief Reviews Technologies That Improve Chronic Care and Help Older Adults Maintain Independence 2Health News:Center for Technology and Aging Brief Reviews Technologies That Improve Chronic Care and Help Older Adults Maintain Independence 3Health News:American Podiatric Medical Association Corrects President's Misstatement on Foot Amputation Costs 2Health News:Johnson City Medical Center Saves $550,000 with Smart Square(R) 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: